Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections

Abstract

Background

Helicobacter pylori (H. pylori) is the causative agent of stomach diseases such as duodenal ulcer and gastric cancer, in this regard incomplete eradication of this bacterium has become to a serious concern. Probiotics are a group of the beneficial bacteria which increase the cure rate of H. pylori infections through various mechanisms such as competitive inhibition, co-aggregation ability, enhancing mucus production, production of bacteriocins, and modulating immune response.

Result

In this study, according to the received articles, the anti-H. pylori activities of probiotics were reviewed. Based on studies, administration of standard antibiotic therapy combined with probiotics plays an important role in the effective treatment of H. pylori infection. According to the literature, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus rhamnosus GG, and Saccharomyces boulardii can effectively eradicate H. pylori infection. Our results showed that in addition to decrease gastrointestinal symptoms, probiotics can reduce the side effects of antibiotics (especially diarrhea) by altering the intestinal microbiome.

Conclusion

Nevertheless, antagonist activities of probiotics are H. pylori strain-specific. In general, these bacteria can be used for therapeutic purposes such as adjuvant therapy, drug-delivery system, as well as enhancing immune system against H. pylori infection.

Background

Helicobacter pylori (H. pylori) is a gram-negative, motile, helical and microaerophilic microorganism that is considered as one of the most successful pathogens due to persistent infection in human stomach [1]. The global prevalence of this bacterium is high, so that according to the latest statistics H. pylori has colonized the stomachs of 4.4 billion people worldwide [2]. There is ample evidence that H. pylori is the etiologic agent of both gastric (gastric malignancy, peptic ulcer, chronic gastritis) and extragastric diseases [3–5]. Depending on the geographical area, the rate of infection with this pathogen varies; frequency of infection with this bacterium is associated with several factors such as virulence factors (e.g. CagA and VacA) and socioeconomic status, for example the rate of infection in some parts of Africa is close to 100% [6]. According to the literature, post-treatment re-infection is common in low-income countries with poor public health policy [7]. Basically all patients infected with this bacterium should be treated; complete eradication of H. pylori improves peptic ulcer and mucosa-associated lymphoid tissue (MALT) lymphoma, as well as reduces the risk of gastric cancer and autoimmune liver disease [8–10]. The most common problems facing gastroenterologists include, (1) antibiotic-resistance phenomenon, (2) persistence of bacteria in latent status, (3) degradation of antibiotics in acidic gastric conditions, (4) re-infection especially in regions with high prevalence, (5) adverse side effects of antibiotics such as diarrhea, nausea, vomit, and abdominal pain, (6) rapid metabolization of antibiotics due to CYP2C19 enzyme, (7) poor compliance of multiple antibiotics [11–13]. In recent years, antibiotic resistance (with high divergence) has led to increased therapeutic failure in eradicating H. pylori with current regimens [14, 15]. In the early 1990s, the eradication rate of the standard triple therapy was more than 90%, however, in recent decades, the effectiveness of this regimen has dropped to less than 70% [16–18]. According to the World Health Organization (WHO) report, the rate of resistance to clarithromycin and metronidazole ranged 14–34% and 20–38%, respectively [19]. Graham et al. suggested that the therapeutic regimens with less than 80% efficacy are considered as treatment failure [20]. Recently, adjuvant therapy with probiotics has received much attention as a new strategy to increase the success of anti-H. pylori therapy [15]. Probiotics are a group of bacteria that confer various health benefits to the host [21]. Intestinal colonization with these microorganisms maintains the integrity of the mucosal immune system and inhibits the side effects associated with antibiotic use [21, 22]. Probiotics are used for purposes such as treating diarrhea and preventing allergic reactions [23]. In vitro studies have shown that some probiotics particularly Lactobacillus spp. possess anti-H. pylori activities [24]. García et al. found that co-existence of Lactobacillus and H. pylori in patients with severe gastrointestinal diseases was significantly lower than control subjects (without clinical symptoms); colonization of Lactobacillus spp. in stomach leads to several events such as reducing gastritis, promoting mucin regeneration, as well as downregulating gene expression in cag pathogenicity island [25]. Therefore, probiotic supplementation is considered as one of the promising solutions for the treatment of H. pylori infection in symptomatic patients [15]. Based on studies, the use of probiotics as a supplement in addition to standard antibiotic treatment significantly improves the eradication rate of H. pylori infection compared to the administration of antibiotics alone [26, 27]. The main purpose of this study was to provide an overview of the benefits of using probiotics in the treatment of H. pylori infection.

H. pylori antibiotic resistance and current treatment regimens

First-line therapy

According to European Helicobacter and Microbiota Study Group (EHMSG) guidelines, triple therapy is still recommended as the first-line treatment for H. pylori infection in areas with low clarithromycin rate [28]. Increasing clarithromycin resistance leads to reduce the eradication rate of clarithromycin-containing triple therapy, for example in Argentina cure rate is estimated at 75% [29]. The situation in South Korea is even worse, so that based on the duration of treatment, the cure rate with this regimen has been estimated at 64% and 66% for 7 and 14 days, respectively [30]. According to the literature, clarithromycin resistance rates are 10.6–25%, 16%, and 1.7–23.4% in North America, Japan, and Europe, respectively [30–33]. On the other hand, metronidazole resistance is also increasing, so that the resistance in European and African countries is 17–44% and 100%, respectively [34–36]. Recently, Yao et al. showed that the rate of infection eradication in type 2 diabetic patients is up to 74% [37]. Bismuth quadruple therapy, a complex regimen containing proton pump inhibitors (PPIs), bismuth salt, tetracycline, and metronidazole is also recommended as second-line (or even first-line) in high clarithromycin resistance areas [38]. In accordance with multicenter randomized controlled trials (RCTs)‏, curing rate of bismuth quadruple therapy is significantly higher than the standard triple therapy (90.4% vs. 83.7%) at the same time (for 14 days) [39]. However, in a meta-analysis study, Luther et al. evaluated nine RCTs, and found that the eradication rate of infection in patients receiving bismuth quadruple therapy was the same as those who had received clarithromycin triple therapy (78.3% vs. 77%) [40]. But it should be noted that bismuth citrate is harmful to human health, so this drug (or even tetracycline) is contraindicated in some areas [41]. In a comprehensive meta-analysis on fourteen RCTs studies, it was shown that the eradication rate of infection with both bismuth and non-bismuth quadruple regimens was 6% higher than sequential treatment [42].

Second-line therapy

Levofloxacin triple therapy‏ and bismuth quadruple therapy are considered as two well-known therapeutic strategies against H. pylori infection [43]. Levofloxacin-containing regimen contains a PPIs plus levofloxacin and amoxicillin [44]. According to the literature, eradication rate of infection in levofloxacin triple therapy and bismuth quadruple therapy is 74.5% and 78%, respectively [43, 45]. Increased resistance to quinolones has now become a major concern in reducing the clinical efficacy of levofloxacin-containing therapy; resistance to quinolones in Europe, America, and Asia is 20%, 15%, and 10% respectively [46]. Due to the adverse event rates of levofloxacin in patients, it is recommended that treatment with levofloxacin be prescribed only in cases of treatment failure [47].

Third-line therapy

In general, third-line therapy is prescribed following antibiotic susceptibility testing (AST) and considered as a rescue regimen in case of failure in the first and second lines of treatment [43]. Nevertheless, due to the impossibility of testing in all areas, therefore therapeutic protocols such as bismuth-based levofloxacin quadruple therapy or rifabutin triple therapy (a PPI, rifabutin, and amoxicillin)‏ are used as ‏ alternative empiric treatments [48]. All three treatment lines are summarized in Fig. 1.

Fig. 1.

Flowchart of the three eradication regimens for the treatment of H. pylori infection

Drawbacks of antibiotic therapy against H. pylori

Overall, there are some drawbacks versus successful antibiotic therapy that include, increasing antibiotic resistance (especially against clarithromycin and metronidazole), unfavorable acidic conditions of the stomach (degradation of antibiotics), non-FDA-approved of some antibiotics (e.g. nitazoxanide), side effects of all antibiotics, as well as toxicity and high price of some drugs [47, 49, 50]. Treatment failure may gradually lead to the progression of the primary infection to more severe complications such as peptic ulcer, MALT lymphoma, and gastric cancer [51]. In summary, probiotics help human body against H. pylori through direct or indirect antagonism interactions including secreting antibacterial substances (lactic acid, short-chain fatty acids, hydrogen peroxide, and bacteriocins), inhibiting bacterial colonization, enhancing mucosal barriers, and regulating the immune responses [52].

Probiotics as anti-H. pylori agents

Comprehensive definition of probiotics

Probiotics are a group of living microorganisms that generally colonize the gastrointestinal tract and have undeniable effects for improving human health [53]. Today, the clinical benefits of probiotics are widely accepted; their therapeutic applications are in disorders such as diarrhea, antibiotic-associated diarrhea, functional digestive involvements, inflammatory bowel disease, cardiovascular diseases, allergic reactions, and cancer [54]. Lactobacillus spp. are one of the most well-known probiotics that their anti-H. pylori properties have been proven [55]. According to the evidence, colonization rate of Lactobacillus spp. in normal human gastric is 0–10³ CFU (resistant to acidic conditions of the human stomach for 2 h); some Lactobacillus strains prevent the persistent colonization of H. pylori due to their specific adhesins [56]. According to the European Helicobacter Pylori Study Group (EHPSG), adjuvant therapy with probiotics can be helpful in increasing the cure rate of infections [57]. In addition to Lactobacillus spp., many other bacteria are accounted as bacterial probiotics against H. pylori; characteristics such as names of probiotics, their potential activity, in-vitro or in-vivo examinations, and country of study are listed in Table 1. However, some probiotics such as Lactobacillus spp. and Bifidobacterium spp. have been used more in clinical trials than other probiotics [58]. According to the literature, administration of a dairy product supplemented with Lactobacillus spp. and Bifidobacterium spp. increases both mucosal and systemic IgA response against to gastrointestinal infections [59]. Sheu et al. showed in their study that a yogurt containing these bacteria could improve the eradication rate of H. pylori infection, and also restore the depletion of Bifidobacterium in stool at the fifth week of treatment [60]. In addition, these bacteria can produce significant amounts of lactic acid in the stomach after successful colonization [61].

Table 1.

List of probiotics with potential activity against H. pylori infection by in vitro and in vivo studies

Probiotic name	Potential activity	Human/animal/in-vitro examination	Country	Ref
L. salivarius WB1004	Inhibition of colonization, lactic acid	BALB/c mice	Japan	[62]
L. acidophilus (johnsonii) La1	Inhibition of colonization, lactic acid, H2O2, bacteriocins	Human	Switzerland	[63]
L. johnsonii La1	Inhibition of colonization, lactic acid, H2O2, bacteriocins	Human	Switzerland	[64]
L. acidophilus CRL 639	Autolysins, lactic acid	In-vitro	Sweden	[65]
L. gasseri OLL 2716	Anti-inflammatory activity, lactic acid	Human	Japan	[66]
L. reuteri	Anti-inflammatory activity (inhibition of IL-8 synthesis), lactic acid	In-vitro	Canada	[67]
L. casei Shirota	Biocine, lactic acid, Inhibition of colonization	Human	Netherlands	[68]
L. casei Shirota	Biocine, lactic acid, Inhibition of colonization	C57BL/6 mice	Greece	[69]
L. brevis	Arginine deiminase activity, inhibition of colonization	Human	Italy	[70]
L. rhamnosus R0011 and L. acidophilus R0052	Inhibition of colonization, lactic acid	C57BL/6 mice	Canada	[71]
L. salivarius	Lactic acid, bacteriocin	In-vitro	Ireland	[72]
L. bulgaricus BB18 and Enterococcus faecium MH3	Lactic acid, bulgaricin BB18, enterocin MH3	In-vitro	Bulgaria	[73]
L. brevis BK11 and E. faecalis BK61	Lactic acid, bacteriocin	In-vitro	Korea	[74]
L. lactis A164 and L. lactis BH5	Lactic acid, lacticin A164, lacticin BH5	In-vitro	Korea	[75]
Bacillus clausii	inhibition of colonization (bacterial cell and spores)	Human	Italy	[76]
B. subtilis	Amicoumacin A	In-vitro	France	[77]
Lactobacilli and Bifidobacteria	Lactic acid	Human	Germany	[78]
Weissella confusa PL9001	Bacteriocin, inhibition of colonization	In-vitro	Korea	[79]
E. faecium GM-1	Lactic acid, bacteriocin?	In-vitro	South Korea	[80]
E. faecium TM39	Lactic acid, bacteriocin	In-vitro	Taiwan	[81]
Saccharomyces boulardii	Anti-inflammatory activity	Human	Romania	[82]
L. reuteri ATCC 55730	Reuterin	Human	Italy	[83]
L. rhamnosus JB3	Antagonist of AI‐2	In-vitro	Taiwan	[84]

Substantial mechanism of probiotics against H. pylori infection

Probiotics have various mechanisms to eradicate or restrict H. pylori growth within the stomach of humans including, (1) inhibition the colonization of H. pylori via conquering gastric epithelial receptors or co-aggregation mechanism, (2) anti-H. pylori activity throughout the production of bacteriocins, organic acids, as well as bio-surfactants, (3) supportive role in intestinal tissues by promoting mucin synthesis, (4) modulation of immune system response, (5), induction of antigen-specific antibodies, and (6) reduction of stomach inflammation (Fig. 2). The details of each of the hypotheses proposed are discussed below.

Fig. 2.

Defenses mechanisms against H. pylori infection which subdivided into two main mechanisms including physiological barriers and immune system. Upon entrance of H. pylori into the stomach, both innate and specific immunity enter the area of infection (lamina propria). Consumption of probiotics has several advantages in strengthening and stimulating immune system versus this pathogen. Antibacterial activities of probiotics direct and indirect are helpful for human health. Therapeutic effects of these bacteria in gastric tract are including immune modulation (via interaction with TLRs), anti-H. pylori activity, co-aggregation of invasive bacteria, decrease pH by secretion of short chain fatty acids, support epithelial barrier integrity, mucin production, as well as promoting immune cells to inhibit gastric inflammatory response particularly IL-8 production, and induction of immunoglobulin secretions

Competition for binding sites

Like other bacteria, attachment is an important step in the continued colonization of H. pylori [85]. According to in vitro studies, L. reuteri inhibits the attachment of H. pylori via competition binding to asialo-GMI and sulfatide receptors [86]. Sakarya et al. showed that S. boulardii blocks the attachment of H. pylori to gastric epithelial cells through binding to sialic acid receptors [87]. Moreover, other probiotics such as L. acidophilus LB, L. johnsonii, L. salivarius, and W. confuse prevent the colonization of this pathogen through specific adhesion molecules [88–90]. Based on studies in thirty C57BL/6 female mice, Johenson et al. found that pre-treatment with L. acidophilus R0052 and L. rhamnosus R0011 completely inhibited the colonization of this bacterium compared to control group [71]. In addition, in a study on 13 patients infected with H. pylori, Myllyluoma et al. found that consuming a solution containing four probiotics for 56 days reduced the rate of infection by 27% [91].

Mucosal barrier

Mucous membranes are one of the first lines of defense to protect humans (or animal) against environmental pathogens; excessive secretion of mucins and large glycoproteins effectively cover the surface of gastrointestinal tracts and prevent the colonization of infectious agents, especially H. pylori [92]. Recent studies have shown that this bacterium inhibits the expression of several mucins genes such as MUC1 and MUC5 [93]. In vitro studies show that some probiotics e.g. L. rhamnosus and L. plantarum induce the expression of MUC2 and MUC3 genes (the most important mucins in gastrointestinal tract), leading to inhibition of H. pylori colonization [94]. Interestingly, Pantoflickova et al. showed in their study that consumption of L. johnsonii thickens the mucosal layer, which in turn prevents bacterial colonization [95].

Probiotics as antibiotics

Scientific studies have shown that probiotics can also act as antibiotic-producing bacteria, and are able to contain the growth of H. pylori by producing antimicrobial substances [96]. Streptomyces spp. are the largest antibiotic-producing probiotics; these bacteria produce a large number of antibiotics such as streptomycin, chloramphenicol, tetracycline, kanamycin, vancomycin, cycloserine, lincomycin, neomycin, cephalosporins, clavulanic acid [97–99]. Moreover, bacitracin as an effective antibiotic on peptidoglycan of Gram-positive bacteria is produced by B. licheniformis and some strains of B. subtilis [100].

Short-chain fatty acids produced by probiotics such as acetic acid, propionic acid, and lactic acid can lower the pH of the environment, leading to unfavorable gastric conditions for H. pylori [101]. Bacteriocins (antibacterial peptides) are other properties of probiotics that in turn have antagonistic activity against the survival of H. pylori [102]. Coconnier et al. first found that the supernatant fluid from Lactobacillus acidophilus LB significantly could reduce the viability of H. pylori [24]. In a clinical trial study, Michetti et al. showed that oral administration of culture supernatant fluid of L. acidophilus strain La1 had anti-H. pylori activity [63]. In later years, discovered that this property was due to antimicrobial nisin A [75]. Bacteriocins are a heterogeneous group of antimicrobial proteins that are mostly produced by lactic acid bacteria [103, 104]. Although studies on the effects of bacteriocin-like compounds against H. pylori are limited, bacteriocins with anti-H. pylori activity are produced by some probiotic genera such as Pediococcus, Lactococcus, Bacillus, Weissella, and Bifidobacterium [74, 105]. Bacteriocins reduce or inhibit the growth of H. pylori by a variety of mechanisms including, inducing pores in membrane, activating of autolytic enzymes, and downregulating expression of vacA, cagA, luxS, and flaA genes [52, 106–108]. In other study, Boyanova et al. introduced seven bacteriocins from L. bulgaricus that were able to kill both antibiotic-susceptible and-resistant bacteria [102]. However, although bacteriocins have been proposed as a new alternative to drug-resistant H. pylori strains, these antimicrobial peptides (AMPs) are strain-specific and are also sensitive to gastrointestinal enzymes [52, 75].

Co-aggregation and auto-aggregation (querish)

Co-aggregation status occurs between different species (or strains) of probiotics and pathogenic strains (heterogeneous bacteria), while in the auto-aggregation status, only species of one genus react with each other [109]. According to in vitro studies, some probiotics such as L. reuteri DSM17648, L. gasseri, and L. johnsonni La1 (NCC533) are able to co-aggregate with H. pylori strains [110, 111].

Immunomodulatory mechanism

Probiotics also modulate the immune system responses; Blum et al. was first showed the role of probiotics in modulating the immune system responses against H. pylori infection [111]. This bacterium increases the inflammatory response by promoting the secretion of TNF-α and IL-8, which in turn lead to the upregulation of gastrin-17, apoptosis, and finally peptic ulcer [91]. Yang et al. found that pre-treatment with L. salivarius in animal model reduced chronic gastritis through the inactivation of JAK1/STAT1 and NF-κB pathways [112]. In addition, probiotics through some processes such as upregulating the expression of MUC3, cyclooxygenase-1, and PGE2, facilitate the secretion of mucin and angiotensin, thus preventing the apoptosis of mucosal cells [113, 114].

Probiotics as delivery system for the treatment of H. pylori infection

Although many people around the world are infected with this bacterium in the first years of life, the search for an effective vaccine began after identification of H. pylori by Varan and Marshall; however, the effectiveness of the vaccine is doubtful, because this bacterium suppresses the immune responses [115]. Until recently, the vaccines entered in phase III clinical trials were stopped due to insufficient immunity against this pathogen [116]. At the moment, Lactobacillus spp. can be used as promising candidates for oral vaccination; the most important reasons are: (1) safety, 2) being immunogenic, 3) low cost, 4) accessibility, 5) ease of administration [117]. Here are some recombinant probiotics containing H. pylori antigens such as Lactococcus lactis (UreB), L. lactis (NapA), L. lactis (CTB-UE), and B. subtilis (UreB); oral administration of each of them leads to an increase in serum levels of IgG and IgA [118–121].

Probiotics and animal models

According to animal studies, researchers have shown the benefits of probiotics including, (1) elimination of H. pylori infection, (2) reduction of gastritis, (3) inhibition of the progression of primary infection to gastric cancer and MALT lymphoma (Table 2). According to animal experiments, probiotic supplementation can reduce the persistent colonization of H. pylori as well as gastric inflammation by modulating pro-inflammatory cytokines i.e. IL-8, IL-12, TNF-α, and H. pylori-specific IgG titer [69, 122–124]. Chronic infection can stimulate the immune system to create favorable conditions to support the growth of bacteria [125–127]. Bacterial virulence factors can disrupt the signaling pathways and cell junctions, leading to the formation of pre-cancerous lesions as hummingbird phenotype [128, 129]. Curing H. pylori infection is considered as the main strategy for preventing gastric MALT lymphoma and can decrease the risk of secondary gastric cancer or relapse of gastric ulcers [130, 131]. Probiotics can reduce the colonization of H. pylori by their protective compounds such as bacteriocins, organic acids, and biosurfactants [104]. According to the literature, H. pylori infection significantly affects the gastric microenvironment by several changes including DNA instability, disruption of NF-κB signaling pathway, as well as differentiation of autoreactive B cells and subsequent malignant transformation by genomic alternations [132, 133]. In general, the use of probiotics effectively modulates immune responses, reduces gastritis by reducing pro-inflammatory cytokines, and ultimately prevents H. pylori-induced gastric malignancies [134–136].

Table 2.

Clinical advantages of probiotics in animal studies

Fist author	Year	Probiotic strain name	Dosage /duration	Animal model	Conclusion remarks	Ref
Ushiyama et al	2003	L. gasseri OLL2716	107 CFU/mL	BALB/c mice	Anti-H. pylori effects Reduction of IL-8	[122]
Sgouras et al	2004	L. casei Shirota	108 CFU/mL, 9 months	C57BL/6 mice	Reducing H. pylori colonization and decrease specific IgG titer	[69]
Henry et al	2004	L. rhamnosus R0011, L. acidophilus R0052	109 CFU/mL, 9 weeks	C57BL/6 mice	Anti-H. pylori effects Reduce gastric inflammation	[71]
Pena et al	2005	L. reuteri 1602, L. paracasei 6798	109 CFU/mL, 12 weeks	C57BL/6 mice	Reducing the TNF-α and IL-12 levels	[123]
Sgouras et al	2005	L. johnsonii La1 L. amylovorus CDE471 L. acidophilus IBB 801	1.5–4 × 108 CFU/mL, 3 months	C57BL/6 mice	Reducing H. pylori colonization and decrease gastric inflammation	[137]
Brzozowski et al	2006	L. acidophilus R0052 L. rhamnosus R0011	2 × 109 CFU/mL, 2 weeks	Mongolian gerbil	Reduction gastrin and gastric inflammation	[138]
Chenoll et al	2011	B. bifidum CECT 7366	109 CFU/mL	C57BL/6 mice	Blocking colonization of H. pylori	[139]
Kuo et al	2013	L. acidophilus, B. lactis	5 × 109 CFU/mL	Mongolian gerbil	Reduction of gastric inflammation	[140]
Kaur et al	2014	P. acidilactici BA28	109 CFU/mL, 24 weeks	C57BL/6 mice	Anti-H. pylori	[141]
Kim et al	2014	P. pentosaseus (SL4)	108 CFU/mL, 6 weeks	C57BL/6 mice	Anti-H. pylori	[142]
Zaman et al	2014	L. reuteri L. johnsonii L. murinus	109 CFU/mL	Mongolian gerbil	Anti-H. pylori	[143]
Matsui et al	2015	L. gasseri SBT2055	109 CFU/mL	C57BL/6 mice	Production of specific IgA, Blocking progression of MALT	[144]
Yu et al	2015	E. faecalis B. longum L. acidophilus	107 CFU/mL	C57BL/6 mice	Reducing gastric inflammation	[145]
Pan et al	2016	L. plantarum ZDY 2013	109 CFU/mL	C57BL/6 mice	Reducing gastric inflammation	[146]
Afsahi et al	2018	L. plantarum ATCC8014	106 CFU/mL, 2 weeks	C57BL/6 mice	Anti-H. pylori Reduction of gastric inflammation	[147]
Chen et al	2018	L. rhamnosus JB3	5 × 107 CFU/mL	C57BL/6 mice	Anti-H. pylori Reduction of gastric inflammation	[148]
Merino et al	2018	L. fermentum UCO-979C	107 CFU/mL	Mongolian gerbil	Inhibited H. pylori SS1	[149]
Lin et al	2020	L. fermentum P2 (P2), L. casei L21 (L21), L. rhamnosus JB3 (JB3)	107 CFU/mL	C57BL/6 mice	Reduction of gastric inflammation	[150]

Probiotics as adjuvant therapy

Therapeutic effects of probiotics against H. pylori infection in children

There is ample evidence of the clinical effects of probiotics in treating and reducing bacterial load in children. Cruchet et al. conducted a randomized double-blind trial on children with asymptomatic H. pylori infection. In their study, the children were divided into five groups, so that four groups received probiotic Lactobacillus strains (live L. paracasei ST11 or L. johnsonii La1, and heat-killed L. paracasei ST11 or L. johnsonii La1),‏ and one group received placebo. They found that the C13UBT value in children receiving live L. johnsonii La1 was significantly lower than other groups [151]. In a similar study, asymptomatic children were randomly treated with three regimens containing standard triple therapy [8 days), L. acidophilus LB (daily for 8 weeks) and, Saccharomyces boulardii plus inulin (daily for 8 weeks). Finally, results showed that the C13UBT value was significantly lower in children receiving triple therapy and Saccharomyces boulardii [152]. Based on several clinical trials, it has been concluded that the rate of eradication of H. pylori infection increases in children receiving probiotic diets (without antibiotics). Some of these studies that suggested clinical efficacy of probiotic supplementation in the eradication of H. pylori infection are listed in Table 3. Based on these studies, probiotics can significantly increase H. pylori eradication rate particularly in patients receiving Lactobacillus spp. and Bifidobacterium spp. supplementation. These probiotics have a high potential against H. pylori infection using various mechanisms [55, 153]. In addition, probiotics can alter the gut microbiota to reduce gastrointestinal symptoms and drug side effects [154, 155].

Table 3.

Available clinical trials of probiotics in the treatment of H. pylori infection in children

First author	Year	Type of study	Eradication therapy	Probiotic regimen	Duration	Cure rate		Statistical significance	Ref
						Case	Control
Gotteland et al	2005	Open randomized	NA	Saccharomyces boulardii, L. acidophilus	8 weeks	12%, 6.5%	0%	p < 0.000	[152]
Sykora et al	2005	Double blind randomized	Omeprazole, amoxicillin, clarithromycin for 7 days	L. casei DN-114 001	2 weeks	84.6%	57.4%	p = 0.0019	[156]
Goldman et al	2006	Double blind randomized	Omeprazole, amoxicillin, clarithromycin for 7 days	B. animalis + L. casei	3 months	45.4%	37.5%	p < 0.01	[157]
Lionetti et al	2006	Double blind randomized	Omeprazole, amoxicillin, clarithromycin, tinidazole (sequential therapy)	L. reuteri ATCC 55,730	20 days	85%	80%	p < 0.009	[158]
Gotteland et al	2008	Double blind randomized	NA	L. jonsonii La1 plus cranberry, L. jonshonii La1, cranberry plus heat-killed L. jonsonii La1	3 weeks	22.9%, 14.9%, 16.9%	1.5%	p = 0.542	[159]
Hurduc et al	2009	Open randomized	Omeprazole, amoxicillin, clarithromycin for 7 days	Saccharomyces boulardi	4 weeks	93.7%	80.9%	p < 0.002	[82]
Szajewska et al	2009	Double blind randomized	Omeprazole, amoxicillin, clarithromycin for 7 days	L. rhamnosus GG	1 weeks	67.6%	68.7%	Not significant	[160]
Boonyaricaikij et al	2009	Single blind	NA	L. gasseri OLL2716	1 years	29.3%	6.6%	p = 0.03	[161]
Tolone et al	2012	NA	Omeprazole, amoxicillin, clarithromycin for 7 days	Probinul-Cadigroup	NA	88.2%	76.4%	p < 0.05	[162]
Zhao et al	2014	prospective randomized controlled study	Omeprazole, amoxicillin, clarithromycin for 7 days	Saccharomyces boulardii	7 days	85%	75.8%	p < 0.05	[163]
Wang et al	2014	NA	Omeprazole, amoxicillin, clarithromycin for 7 days	L. acidophilus, B. bifidum	2 weeks	83.7%	64.4%	p < 0.05	[164]
Akcam et al	2015	Open randomized	triple therapy (lansoprazole, amoxicillin, clarithromycin for 14 days)	L. casei, L. acidophilus, B. lactis	2 weeks	66.6%	68.9%	p = 0.78	[165]
Zhu etal	2017	Double blind randomized	Sequential, Triple therapy	Sequential-Lactobacillus, triple-Lactobacillus therapy	NA		Sequential-Lactobacillus and triple-Lactobacillus better than any of them alone (P < 0.05)	p < 0.01	[166]

Recently, two meta-analyses have evaluated the clinical effects of probiotics in the treatment of H. pylori infection in children. Li et al. evaluated data from 508 sick children; the pooled ORs for H. pylori eradication rate by intention-to-treat (ITT) and per-protocol (PP) analysis in children who had received probiotic supplementation and control group was 1.96 (95% CI: 1.28–3.02) and 2.25 (95% CI: 1.41–3.57), respectively [167]. In another study, Fang et al. analyzed the clinical efficacy of Lactobacillus-supplemented triple therapy in 484 children, and found that the relative risk (RR) of curing rate in the Lactobacillus-treated group was significantly higher than control group (RR: 1.19; 95% CI: 1.07–1.33); diarrhea was also significantly reduced (RR: 0.3; 95% CI: 0.10–0.85) in this group [168].

Therapeutic effects of probiotics against H. pylori infection in adults

In the present study we evaluated all studies conducted on the effect of probiotics against H. pylori infection in human (Table 4).

Table 4.

Recent meta-analysis studies on the effect of probiotics in the treatment of H. pylori infection

First author	Year	Sample size	Eradication regimen	Probiotics	Conclusion remarks	Significance	Ref
Tong et al	2007	1671	First-line and second-line therapy (triple and bismuth containing quadruple therapy)	B. clausii, Lactobacillus, Saccharomyces	ER: RR: 1.84; 95% CI: 1.34–2.54 AE: 0.44; 95% CI: 0.3–0.6	Both significant AE was adverse event ER was eradication rate	[169]
Sachdeva et al	2009	963	First-line therapy (Triple and Quadruple)	Lactobacillus, Bifidobacterium	ER: 1.91; 95% CI: 1.3–2.6 AE: 0.51; 95% CI: 0.1–2.5 but AE was not significant	Reduction of adverse event rate was not significant	[170]
Zou et al	2009	1372	First-line therapy (Triple)	Lactobacillus	ER: 1.78; 95% CI: 1.21–2.62 AE: OR was 0.49 (95% CI = 0.24–1.02)	Both significant	[171]
Szajewska et al	2010	1307	First-line therapy (Triple)	S. boulardii	ER: 1.13, 95% CI 1.05–1.21 AE: RR 0.46, 95% CI 0.3–0.7	Both significant	[172]
Zheng et al	2013	1163	First-line therapy (Triple)	Lactobacillus	RR: 1.14; 95% CI: 1.06–1.22 (significant increase of eradication rate) but no significant reduction of overall adverse event	Reduction of adverse event rate was not significant	[173]
Wang et al	2013	1469	First-line and second-line therapy (triple and bismuth containing quadruple therapy)	Bifidobacterium, Lactobacillus	ER: 2.066 (95% CI, 1.398–3.055 AE: 0.305; 95% CI, 0.117–0.793)	Both significant	[174]
Zhu et al	2014	2259	standard triple H. pylori	Lactobacillus, Bifidobacterium, Saccharomyces	ER: 1.67 (95%CI: 1.38–2.02) AE: (OR = 0.49, 95%CI: 0.26–0.94	Both significant	[175]
Dang et al	2014	4459	First-line therapy (Triple)	L. acidophilus, L. casei DN-114001, L. gasseri, Bifidobacterium infantis 2036	Curing rate was significantly increase in probiotics (RR: 1.11; 95%CI: 1–1.1) as well as reduce of adverse event (RR: 0.73; 95%CI: 0.5–0.9)	Both significant	[176]
Zhang et al	2015	6997	First-line and second-line therapy (triple And bismuth containing quadruple therapy)	Lactobacillus, Bifidobacterium, Streptococcus, Saccharomyces, Enterococcus, Bacillus	ER: RR = 1.13; 95%CI: 1.10–1.16 AE: RR = 0.59; 95%CI: 0.48–0.71	Both significant	[177]
Lu et al	2016	3349	First-line therapy (triple)	Lactobacilli, Bifidobacteria, Bacillus clausii, E. faecium	ER: OR 1.44, 95% CI: 0.87, 2.39 but not significant AE: probiotics did improve the adverse effects OR 0.56, 95% CI: 0.31, 1.01	Both not significant	[178]
Lu et al	2016	2306	First-line therapy (Triple)	Lactobacillus, Bifidobacterium	Eradication rate in probiotic supplementation group was significantly higher than control (RR: 1.15; 95%CI: 1.1–1.2) and reducing adverse event (RR: 0.71; 0.5–0.9) probiotic supplementation increased eradication of triple therapy in both 7 and 14-days	Both significant	[179]
Si et al	2017	2466	First-line therapy (bismuth containing quadruple therapy)	Lactobacillus	Eradication rate was significant increase in probiotics (89% vs. 84.7% for first-line) (91% vs. 73.8% for second-line)	significant	[180]
Losurdo et al	2018	NA	NA	Lactobacillus	ER: UBT value: 8.61% vs. 0.19% AE: 1, 95%CI: 0.06–18.08 not siginificANT FOR AE	Reduction of adverse event rate was not significant	[181]
Shi et al	2019	8924	First-line therapy (Triple and Quadruple)	Lactobacillus	RR: 1.14; 95%CI: 1.10–1.18 (significant increase of eradication rate) and reduced side effects	Both significant	[182]
Yu et al	2019	724	First-line therapy (Triple	Lactobacillus	Eradication rate was significantly increase in Lactobacillus supplement group (RR: 1.1; 95%CI: 1–1.2) and derease significantly adverse event (RR: 0.36; 95%CI: 0.1–0.7)	Both significant	[183]
Pourmasoumi et al	2019	525	First-line therapy (Triple and Quadruple)	Lactobacillus, Bifidobacterium Saccharomyces	Eradication: RR: 1.28; 95% CI: 1.15–1.43 Adverse: RR: 0.90; 95% CI: 0.69–1.16	Both significant	[184]
Zhou et al	2019	3592	First-line therapy (Triple)	S. boulardii	ER: 1.09, 95% CI:1.05‐1.13 AE: RR = 0.33, 95%CI:0.16‐0.69	Both significant	[185]

According to the literature, probiotic supplementation increases the rate of infection eradication during first- and second-line treatment (Table 4). However, according to some studies, probiotic supplementation was significantly ineffective in improving the eradication rate of infection; in their network meta-analysis, Wang et al. found that probiotics in combination with triple therapy could not increase the eradication rate of infection [186]. In addition, most studies have shown that adverse events were significantly lower in the group receiving probiotics plus antibiotic than in the control group, but this was not the case in a number of other studies [178, 181, 185]. It is important to note that probiotics alone are not effective, but can only be prescribed as adjunctive therapy in clinical improvement [174]. In recent, using data of 467 patients with treatment failure, we showed that Lactobacillus-containing bismuth quadruple therapy for 10 days, significantly increases the cure rate of H. pylori infection in patients with previous treatment failure (RR: 1.77; 95% CI: 1.11–2.83; p value: 0.01. (Among all probiotics, the clinical effects of Lactobacillus spp. and S. boulardii have been further studied; S. boulardii and Lactobacillus species such as L. casei, L. reuteri, and L. rhamnosus GG are all safe and improve the quality of treatment [172, 183, 185]. It seems that multi-strain probiotics supplementation has a significant effect on the treatment of infection [173, 181, 182]. In accordance with this theory, Lu et al. showed that multi-strain probiotics (Bacillus, Saccharomyces, Streptococcus, Bifidobacterium, and Lactococcus) significantly increased the eradication rate of infection (RR: 1.12; 95% CI: 1.07–1.18; p value: 0.00001); however, heterogeneity was significant in their study [179]. In general, according to various studies, probiotic supplements are considered as a reliable strategy to increase the quality of treatment in individuals with treatment-naïve or treatment-failure.

Use of probiotics in the prevention of H. pylori infection

Vaccine prophylaxis as a suitable strategy has become a big challenge for this bacterium, because in many people it is colonized in childhood, the rate of infection is high, as well as the immunology of the stomach is unclear [187]. According to the results of a cohort study on 308 H. pylori-negative children, it was defined that the infection rate in groups receiving L. gasseri OLL2716 (LG21) was less than control group (4.1% vs 8.1%, respectively); nevertheless; the results was not significant [161].

Diversity of gut microbiota during H. pylori treatment with probiotic supplementation

In total, about 100 trillion bacteria have been colonized in the human body. Gastrointestinal microflora is one of the most complex microbial ecosystem, and protects host against colonization of pathogenic microorganisms [188, 189]. Imbalance in this ecosystem due to the excessive use of antibiotics leads to several disorders such as inflammatory bowel disease (IBD), metabolic syndrome and even colon cancer [190–192]. According to the literature, H. pylori infection can cause dysbiosis in the intestinal microbiota, but short- and long-term changes in human gut microbiome after H. pylori infection are controversial [193, 194]. In their meta-analysis, Ye et al. showed that the during long-term follow-up the frequency of Actinobacteria and Bacteroidetes was reduced; they also found that the frequency of Enterococcus and Enterobacteriaceae was increased, while Proteobacteria after a short-term increase, again returned to their normal amounts during long-term follow-up [194]. There is limit information about the effects of probiotics on gut microbiota during the H. pylori infection. In their study, Oh et al. evaluated functional changes in intestinal microbiota using the Illumina MiSeq system after standard anti-H. pylori treatment and probiotic supplementation. They found that the expression of genes involved in selenocompound metabolism pathway was significantly reduced in patients receiving probiotic; this phenomenon can be led to a reduction in side effects such as intestinal irritation as well as antibiotic resistance [195]. Wang et al., recently explored the effect of anti-H. pylori concomitant therapy vs. concomitant therapy plus probiotic supplementation (with S. boulardii) on the alternation of gut and throat microbiota in human subjects. They showed that there was significant quantitative and qualitative alternations in microbiota composition in both concomitant anti-H. pylori therapy and concomitant therapy plus probiotic supplementation groups. Nevertheless, in probiotic supplementation group most changes in gut microbiota reverted after 71 days (except for Bacteroides spp. and yeast counts), whereas changes in the throat microbiota were persistent. In addition, antibiotic resistance rate of bacteria such as Enterobacteriaceae, Enterococcus spp., and Bacteroides spp. was significantly higher in patients receiving concomitant therapy than patients receiving concomitant therapy plus probiotic supplementation. Moreover, their study revealed that co-administration of probiotics in the treatment of H. pylori infection could be more effective than post-antibiotic supplementation [196]. In a recent study by Cárdenas et al. the clinical effects of S. boulardii CNCM I-745 on gut microbiota of patients receiving standard anti-H. pylori therapy was evaluated. According to their results, supplementation with this probiotic significantly reduced gastrointestinal symptoms (p = 0.028); alterations in gut microbiota was also seen with higher abundance of Enterobacteria and lower abundance of Bacteroides and Clostridia upon treatment completion (p = 0.0156) [197]. In general, the antimicrobial activity of probiotics kills or inhibits the growth of resistant bacteria and ultimately reduces antibiotic resistance [195, 196]. According to information at https://clinicaltrials.gov/, all clinical trial studies on the effects of probiotic supplements on the eradication of H. pylori by August 2021 are listed in Table 5.

Table 5.

Clinical trials on the role of probiotics in treating H. pylori infections (https://clinicaltrials.gov/)

Row	Identifier	Start year	Participants	Allocation	Intervention model	Masking	Primary Purpose	Status	Country
1	NCT04319991	2019	100	Randomized	Parallel assignment	Single (Participant)	Supportive Care	Recruiting	Taiwan
2	NCT01115296	2010	100	Randomized	Parallel assignment	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	Treatment	Unknown	Italy
3	NCT03150394	2017	80	Randomized	Parallel assignment	Double (Participant, Investigator)	Treatment	Unknown	Spain
4	NCT04178187	2019	800	Randomized	Parallel assignment	Single (Participant)	Treatment	Recruiting	Greece
5	NCT01969331	2008	804	Randomized	Parallel assignment	Triple (Participant, Care Provider, Investigator)	Treatment	Completed	Croatia
6	NCT02645201	2016	0	Randomized	Parallel assignment	Triple (Participant, Care Provider, Investigator)	Treatment	Withdrawn	Belgium, Croatia, Germany, Israel, Slovenia
7	NCT03220542	2016	360	Randomized	Factorial assignment	Single (Participant)	Treatment	Unknown	Korea
8	NCT03722433	2018	200	Randomized	Parallel assignment	Double (Participant, Care Provider)	Treatment	Unknown	Taiwan
9	NCT03997279	2019	200	Randomized	Parallel assignment	Triple (Participant, Care Provider, Investigator)	Treatment	Unknown	Sebria
10	NCT03377933	2019	40	N/A	Single group assignment	None (Open Label)	Treatment	Unknown	China
11	NCT04473079	2020	100	Randomized	Parallel assignment	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	Supportive Care	Recruiting	Thailand
12	NCT04527055	2020	252	Randomized	Parallel Assignment	Single (Outcomes Assessor)	Treatment	Enrolling by invitation	Taiwan
13	NCT03297242	2017	30	N/A	N/A	N/A	N/A	Unknown	China
14	NCT04786938	2016	63	Randomized	Parallel assignment	Single (Participant)	Treatment	Completed	Ecuador
15	NCT02689583	2016	3000	Randomized	Parallel assignment	Single (Participant)	Treatment	Unknown	China
16	NCT03688828	2018	776	Randomized	Parallel assignment	Triple (Participant, Investigator, Outcomes Assessor)	Treatment	Recruiting	China
17	NCT03404440	2016	56	Randomized	Parallel assignment	Double (Participant, Investigator)	Treatment	Completed	Italy
18	NCT01456728	2011	56	Randomized	Parallel assignment	Double (Participant, Investigator)	Treatment	Completed	Bulgaria
19	NCT02051348	2014	24	Non-Randomized	Crossover assignment	Single (Participant)	Treatment	Completed	Ireland

Disadvantages and limitations

Despite extensive research on the effectiveness of probiotics in eradicating H. pylori infection, there are many challenges in this filed. Due to differences in study design, duration of treatment, and variety of probiotics between clinical trial studies, there is no a reliable homogeneity between them, which in turn affects the interpretation of results. In addition, due to the small sample size of studies, more research needs to be done with larger populations. Unfortunately, in some studies, there is no significant difference between the probiotic supplement group and the control group. Finally, although the exact role of probiotics in the prevention or treatment of H. pylori remains unknown, consumption of probiotics may be associated with side effects such as increasing in serum histamine and also digestive disorders [198].

Conclusions and future perspectives

H. pylori is one of the most successful pathogens in the gastrointestinal tract, which through its virulence factors creates a complex interaction with the human host. Chronic infection caused by this bacterium leads to severe clinical outcomes. The frequency with this bacterium is high in developing countries and poor socio-economic conditions, so that people living in these conditions are generally at high risk for re-infection. Moreover, self-medication with antibiotics on the one hand, and the spread of resistant strains on the other hand, all are considered as a serious threat for the successful eradication of this bacterium. Over the decades, the controversial results of all conducted studies about the treatment of H. pylori infection have been led to the failure to the eradication of this pathogen. Hence, probiotics have been considered by many researchers around the world. In the present study, based on in vitro, animal studies, and human clinical trials, we demonstrated the beneficial effects of probiotics against H. pylori infection. However, those alone are not effective in treating the bacterial infection. In addition, the anti-H. pylori activity of probiotics is strain-specific and remains as a mysterious phenomenon. To date, the therapeutic effects of probiotics against resistant strains of the bacterium have not been evaluated, and whole genome sequencing may solve the existing puzzles. It seems that to decrease the heterogeneity of results and make better decisions, future studies should focus on items such as genus/species, dosage, formulation, and treatment course.

Authors' contributions

1. MK1 have contributed to design of the work. 2. MK2 have drafted the work and substantively revised it. All authors read and approved the final manuscript.

Funding

We have not received any funding for this research.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

Not applicable (this paper was provided based on researching in global databases).

Consent for publication

Not applicable.

Competing interests

There is no any conflict of interest among the all authors.